GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

lirilumab   Click here for help

GtoPdb Ligand ID: 9310

Synonyms: 1-7F9 | BMS-986015 | IPH2102
Immunopharmacology Ligand
Compound class: Antibody
Comment: Lirilumab (BMS-986015) is a fully human monoclonal antibody (mAb) which targets the KIRD2 subgroup of killer cell immunoglobulin like receptors (KIRs) on natural killer cells [1], being developed as an immuno-oncology clinical candidate. Identified targets include KIR2DL1, KIR2DL2, KIR2DL3, KIR2DS1 and KIR2DS2. Genes of KIR proteins are listed in HGNC family Killer cell immunoglobulin like receptors (KIR). ia an IgG4 isotype antibody considered suitable for a blocking , non-depleting mAb with clinical utility.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Classification Click here for help
Compound class Antibody
International Nonproprietary Names Click here for help
INN number INN
9415 lirilumab
Synonyms Click here for help
1-7F9 | BMS-986015 | IPH2102
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 423
Other databases
GtoPdb PubChem SID 318164829
Search PubMed clinical trials lirilumab
Search PubMed titles lirilumab
Search PubMed titles/abstracts lirilumab